Does Pennsylvania Medicaid Cover Wegovy or Zepbound? What Ended in January 2026

No. Pennsylvania Medicaid has not covered Wegovy, Zepbound or any other GLP-1 for overweight or obesity since January 1, 2026, ending a benefit it had offered since January 2023.^[1] As of November 2026 the drugs are still covered with prior authorization for other accepted uses, including diabetes, moderate to severe sleep apnea, heart-risk reduction and the liver disease MASH.^[2][4] Members under 21 are a separate case, because federal child-health rules require the state to review them for medical necessity.^[7]

What ended on January 1, 2026?

Three things happened on the same date. Coverage for weight loss stopped, Saxenda left the program for every use, and all existing GLP-1 authorizations were canceled.^[2] That last step reached people who were not taking the drugs for weight. Authorizations ended on December 31, 2025 “regardless of the condition being treated,” so a person with diabetes or sleep apnea needed a new approval too.^[2] A deputy secretary told the state’s advisory committee there was “no grandfathering.”^[7]

Federal law makes weight-loss drugs an optional Medicaid benefit, and the state cited that provision.^[2][9] CMS approved the matching state plan change on March 4, 2026, backdated to January 1, and its text says GLP-1 agents “are not covered for weight loss.”^[8] The state’s published estimate puts the savings at $348.333 million in total funds for fiscal 2025–26 ($112.965 million of it state money) and $836.000 million for 2026–27 ($266.684 million state).^[1]

People pushed back quickly. By the first full week of January the department counted 1,112 appeals, 68 of them for people under 21. About 900 challenged the notice that existing approvals would end.^[7]

When does Pennsylvania Medicaid still pay for a GLP-1?

Every GLP-1 prescription needs prior authorization, and each use has its own test.^[4] These are the main requirements in the handbook pages dated March 2, 2026, which the department still posted on November 6, 2026.

Prescriptions are limited to one month’s supply per fill.^[4] Outside the heart and liver uses, a request also needs a recent six-month trial of diet and activity changes, or a medical reason treatment cannot wait.^[4] The handbook adds a useful safety valve: a physician reviewer who finds the drug medically necessary can approve it even when the listed criteria are not met.^[4] That clause does not revive coverage for obesity, which the same pages exclude.^[4]

The sleep apnea test deserves attention if you are comparing notes. Zepbound’s label covers moderate to severe sleep apnea in adults with obesity, while Pennsylvania asks for a BMI of at least 35.^[13][4] Our guide to Zepbound for sleep apnea explains the trial data behind that use, and the guide to GLP-1s and MASH does the same for the liver.

Which drug will Pennsylvania Medicaid approve first?

Usually Ozempic. Before 2026, Wegovy and Zepbound were both preferred; the state moved them to non-preferred and says it wants switches to favor the most cost-effective option, naming Ozempic.^[10] Under the March 2026 pages, Wegovy generally requires failure of Ozempic first, Mounjaro requires failure, contraindication or intolerance to Ozempic and Wegovy, and Zepbound adds Mounjaro to that chain.^[4] Wegovy 2.4 mg has an alternate route: finish titration to 2 mg and give a medical reason for the higher dose.^[4]

That order is about to change. The drug list published for January 4, 2027 makes the Wegovy pen, the Wegovy tablet and the Zepbound KwikPen preferred, and moves Victoza to non-preferred.^[6] Obesity stays out, since the list decides which drug is favored for a covered use and the exclusion sits in the state plan.^[6][8]

Preferred status does not remove prior authorization here; each of these entries still carries it.^[5][6] We found no updated step language to go with the 2027 list as of November 6, 2026, so ask your prescriber to check the handbook pages before filing a request after that date.

What about members under 21?

The department told its advisory committee that the cutoff does not apply the same way to children. Early and Periodic Screening, Diagnostic and Treatment rules require all medically necessary services for people under 21, even when an adult benefit does not exist.^[7] The state said it had told its plans to pay attention to this. A consumer representative at the same meeting reported uneven results, saying some plans “seem to have gotten this memo. Others less so.”^[7] A family that gets a flat “not covered” for a minor should ask for a medical necessity review under EPSDT by name.

How do you appeal a denial in Pennsylvania?

An appeal can help if the denial concerns a covered use, such as a dispute over whether your sleep apnea documentation is enough. It has little to work with if the only diagnosis on the request is obesity, because the department does not review those requests for medical necessity.^[7] The route depends on how you get your benefits, and the deadline printed on your notice controls.

• Managed care (HealthChoices). The state’s member template gives 60 days from the notice to file a grievance with the plan, then 120 days from the mail date of the plan’s decision to ask for a Fair Hearing.^[11]
• Fee-for-service. State regulations generally give 30 days from the date of written notice.^[12]
• Staying on the drug. Continued coverage during an appeal depends on acting fast. The same template uses 10 days from the notice date.^[11] Read your own notice, since this window varies between versions.

Our walkthrough of prior authorization and appeals covers what to put in the file.

What are the options if you lost coverage?

Pennsylvania did not leave obesity drugs out altogether. Phentermine capsules and tablets are preferred and available without prior authorization within quantity limits, and non-preferred drugs in that class, such as orlistat and phentermine-topiramate, can be requested with one.^[3][5] Our comparison of phentermine and a GLP-1 shows how far apart the results are.

Paying cash is the other route. Lilly’s savings card for insured patients excludes anyone enrolled in Medicaid, so a copay card will not help.^[14] Self-pay prices as of the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up for Lilly’s Zepbound KwikPen or vial, when each refill comes within 45 days.^[14][15] Read each offer’s terms for government-program limits before you enroll. Our list of the cheapest GLP-1 routes without insurance compares them.